These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778 [TBL] [Abstract][Full Text] [Related]
24. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655 [TBL] [Abstract][Full Text] [Related]
25. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. McKeage K Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694 [TBL] [Abstract][Full Text] [Related]
26. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352 [TBL] [Abstract][Full Text] [Related]
28. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Kay GG; Staskin DR; MacDiarmid S; McIlwain M; Dahl NV Clin Drug Investig; 2012 Oct; 32(10):707-14. PubMed ID: 22909146 [TBL] [Abstract][Full Text] [Related]
29. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder. Ho C Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ; Lemack GE; Foote JE; Trop CS Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264 [TBL] [Abstract][Full Text] [Related]
31. Transdermal oxybutynin: sticking to the facts. Cartwright R; Cardozo L Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979 [TBL] [Abstract][Full Text] [Related]
32. [Intravesical oxybutynin treatment for neurogenic detrusor overactivity : Efficacy and safety data from clinical practice with the first intravesical oxybutynin treatment authorized in Germany]. Schindler O; Ho H; Leidl Q; Angermund A; Elishar R; Frech-Dörfler M; Hirsch A; Kalke YB; Kirschner-Herrmanns R; Tornic J; Queissert F; Rahnama'i S; Rehme C; Reitz A; Schmitz F; Schultz-Lampel D; Gedamke M Urologie; 2024 Jul; 63(7):693-701. PubMed ID: 38755461 [TBL] [Abstract][Full Text] [Related]
33. The value of oxybutynin in transdermal patches for treating overactive bladder. Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. Wang CC; Jiang YH; Kuo HC Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445 [TBL] [Abstract][Full Text] [Related]
35. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin. Saltzstein L Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342 [TBL] [Abstract][Full Text] [Related]